With approval, Alnylam enters the ATTR-CM drug race

Morning! Today, we have plenty of interesting content from yesterday’s STAT Breakthrough Summit East in New York. Also, Alnylam wins an important approval for ATTR-CM. 

Alnylam’s Amvuttra enters ATTR-CM drug race

The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to compete with Pfizer’s Vyndamax and BridgeBio’s Attruby. Priced at $476,000…